[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351393-105":59,"doc-detail-351393-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-management-of-cancer-after-kidney-transplantation","Clinical management of cancer after kidney transplantation","","Advances in immunosuppressive therapy have improved short-term graft survival after kidney transplantation, but they have also reshaped long-term disease patterns. Cancer persists as a major barrier to long-term survival because impaired graft function and immunosuppressive drugs increase malignancy risk. This review outlines prevention, screening, and treatment strategies, covering immunosuppressive medication optimization, risk-adapted screening, and post-diagnosis management combining localized resection with systemic chemotherapy and immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-management-of-cancer-after-kidney-transplantation/351393/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-management-of-cancer-after-kidney-transplantation/351393.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cancer a significant challenge after kidney transplantation?","Question",{"text":112,"@type":113},"Long-term immunosuppression creates an immunological environment that makes cancer a major determinant of graft and recipient outcomes. Cancer accounts for a substantial share of post-transplant mortality and negatively affects quality of life and long-term survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does immunosuppression influence cancer risk in kidney transplant recipients?",{"text":117,"@type":113},"Immunosuppressive therapy increases the risk of malignancy compared with the general population and dialysis patients. Cancer risk is often quantified using the standardized incidence ratio (SIR), which is reported to be around threefold for all cancers in recipients.",{"name":119,"@type":110,"acceptedAnswer":120},"What prevention and screening approaches does the review emphasize?",{"text":121,"@type":113},"Primary prevention includes appropriate selection and maintenance of immunosuppressive medications, careful consideration of transplant indications for patients/donors with prior cancers, and vaccination. Secondary prevention focuses on effective, risk-adapted cancer screening for high-risk recipients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351393,1790161662,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Review  \nPUBLISHED 25 March 2026  \nDOI 10.3389/fimmu.2026.1784083  \nOPEN ACCESS  \nEDITED BY  \nPiergiorgio Messa, University of Milan, Italy  \nREVIEWED BY  \nDejun Kong,  \nLiver Transplantation Center, China Tess Van Meerhaeghe,  \nUniversite´ Libre de Bruxelles, Belgium  \n*CORRESPONDENCE  \nTakahisa Hiramitsu  \n [thira@nagoya2.jrc.or.jp](thira@nagoya2.jrc.or.jp)  \nRECEIVED 09 January 2026  \nREVISED 07 March 2026  \nACCEPTED 10 March 2026  \nPUBLISHED 25 March 2026  \nCITATION  \nHiramitsu T, Ienaga A, Shimamoto Y, Himeno T, Hasegawa Y, Futamura K, Okada M, Narumi S and Watarai Y (2026) Clinical management of cancer after kidney transplantation.  \nFront. Immunol. 17:1784083 .  \ndoi: 10.3389/fimmu.2026.1784083  \nCOPYRIGHT  \n© 2026 Hiramitsu, Ienaga, Shimamoto, Himeno, Hasegawa, Futamura, Okada, Narumi and Watarai. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nClinical management of cancer after kidney transplantation  \nTakahisa Hiramitsu*, Ayano Ienaga, Yuki Shimamoto, Tomoki Himeno, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Shunji Narumi and Yoshihiko Watarai  \nDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan  \nAdvances in immunosuppressive therapy have markedly improved short-term graft survival post-kidney transplantation (KT); however, these advances have also profoundly altered long-term disease patterns in transplant recipients. Cancer remains a major barrier limiting improvements in long-term survival. Kidney transplant recipients are at increased risk of malignancy owing to impaired graft function and immunosuppressive medications. To improve cancer-related outcomes, comprehensive strategies encompassing prevention, early detection through screening, and appropriate treatment are required. Primary prevention includes the appropriate selection and maintenance of immunosuppressive medications, careful consideration of KT indications for recipients and donors with previously treated cancers, and vaccination. Secondary prevention requires effective, risk-adapted cancer screening in high-risk kidney transplant recipients. Following a cancer diagnosis, management includes localized resection and systemic therapy for primary, recurrent, or refractory disease. Systemic therapy includes chemotherapy and immunotherapy, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, which may affect graft function and cause treatment-specific adverse effects. Additionally, immunosuppressive medications often require modification to minimize the risk of graft rejection while maintaining a low likelihood of recurrence. In this review, we summarize current strategies for cancer prevention, screening, and treatment following KT.  \nKEYWORDS  \nCAR-T cell therapy, immune checkpoint inhibitors, immunosuppression, kidney transplantation, post-transplant cancer  \n1 Introduction  \nKidney transplantation (KT) is the optimal treatment for end-stage kidney disease, providing superior survival and quality of life compared with dialysis (1–5) . Preservation of long-term graft function is essential to maximize these benefits. To prevent the development of de novo donor-specific anti-human leukocyte antigen antibodies and subsequent rejection, immunosuppressive therapy remains indispensable post-KT (6–9) . However, long-term immunosuppression creates a unique immunological environment in which cancer has emerged as a major determinant of graft and recipient outcomes (10–13) . Consequently, cancer prevention, early detection, and treatment represent major clinica","cbCaimXZOKEC0GIm","https://ap.wps.com/l/cbCaimXZOKEC0GIm","pdf",634495,13,"English","# Introduction\n# Cancer after kidney transplantation\n## Epidemiology","[{\"question\":\"Why is cancer a significant challenge after kidney transplantation?\",\"answer\":\"Long-term immunosuppression creates an immunological environment that makes cancer a major determinant of graft and recipient outcomes. Cancer accounts for a substantial share of post-transplant mortality and negatively affects quality of life and long-term survival.\"},{\"question\":\"How does immunosuppression influence cancer risk in kidney transplant recipients?\",\"answer\":\"Immunosuppressive therapy increases the risk of malignancy compared with the general population and dialysis patients. Cancer risk is often quantified using the standardized incidence ratio (SIR), which is reported to be around threefold for all cancers in recipients.\"},{\"question\":\"What prevention and screening approaches does the review emphasize?\",\"answer\":\"Primary prevention includes appropriate selection and maintenance of immunosuppressive medications, careful consideration of transplant indications for patients/donors with prior cancers, and vaccination. Secondary prevention focuses on effective, risk-adapted cancer screening for high-risk recipients.\"}]","Clinical management of cancer after kidney transplantation | PDF",1790093984,33]